Principal Investigator
Sangeetha Venugopal
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250884
Clinical Trial Summary
A Phase 2 Study Evaluating Olutasidenib in patients with IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-Risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Leukemia
Contact Information
Phone Number
305-243-2647